ReviewJournal of fungi (Basel, Switzerland)2020
Host Defense Peptides as Templates for Antifungal Drug Development.
Review in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Bridging the "Valley of Death" in Antifungal Therapy: Next-Generation Biomimetic and Exosome-Inspired Nanocarriers for Invasive Candidiasis.Journal of fungi (Basel, Switzerland) · 2026Review
- Antibacterial mechanism of hyper-branched poly-L-lysine against methicillin-resistantFrontiers in microbiology · 2025Article
- Screening sensibility and antifungal activity after topical application of a synthetic lactoferrin-derived antimicrobial peptide.American journal of translational research · 2024Article
- Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance.RSC medicinal chemistry · 2023Review
- Unnatural helical peptidic foldamers as protein segment mimics.Chemical Society reviews · 2023Review
- Repurposing the FDA-approved anticancer agent ponatinib as a fluconazole potentiator by suppression of multidrug efflux and Pma1 expression in a broad spectrum of yeast species.Microbial biotechnology · 2022Article
- Therapeutic Effect of an Antibody-Derived Peptide in aInternational journal of molecular sciences · 2021Article
- Metamorphic Protein Folding Encodes Multiple Anti-Pathogens (Basel, Switzerland) · 2021Article
- Antifungal Peptides.Journal of fungi (Basel, Switzerland) · 2021Article
- In Silico Predicted Antifungal Peptides: In Vitro and In Vivo Anti-Journal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Current treatment for invasive fungal diseases is limited to three classes of antifungal drugs: azoles, polyenes, and echinocandins. The most recently introduced antifungal class, the echinocandins, was first approved nearly 30 years ago. The limited antifungal drug portfolio is rapidly losing its clinical utility due to the inexorable rise in the incidence of invasive fungal infections and the emergence of multidrug resistant (MDR) fungal pathogens. New antifungal therapeutic agents and novel approaches are desperately needed. Here, we detail attempts to exploit the antifungal and immunoregulatory properties of host defense peptides (HDPs) in the design and evaluation of new antifungal therapeutics and discuss historical limitations and recent advances in this quest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.